Authors: Bordin, V Giani, L Meregalli, S Bukovec, R Vaghi, MM Mandala, M Paolorossi, F Ardizzoia, A Tancini, G Barni, S Frigerio, F Fumagalli, L Bordoni, A Valusani, G Di Felice, G Lissoni, P

Citation: V. Bordin et al., Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients, UROL INTERN, 64(1), 2000, pp. 3-8

Authors: Lissoni, P Barni, S Mandala, M Ardizzoia, A Paolorossi, F Vaghi, M Longarini, R Malugani, F Tancini, G

Citation: P. Lissoni et al., Decreased toxicity and increased efficacy of cancer chemotherapy using thepineal hormone melatonin in metastatic solid tumour patients with poor clinical status, EUR J CANC, 35(12), 1999, pp. 1688-1692

Authors: Lissoni, P Tancini, G Paolorossi, F Mandala, M Ardizzoia, A Malugani, F Giani, L Barni, S

Citation: P. Lissoni et al., Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: A phase II study, J PINEAL R, 26(3), 1999, pp. 169-173

Authors: Lissoni, P Paolorossi, F Mandala, L Fumagalli, L Ardizzoia, A

Citation: P. Lissoni et al., Melatonin plus interleukin-2 is more effective as neuroimmunotherapy than melatonin plus somastatin analogs and bromocriptine as polyneuroendocrine therapy in untreatable advanced solid tumor patients, INT J IMM T, 15(2), 1999, pp. 67-72

Authors: Lissoni, P Mandala, M Giani, L Brivio, F Paolorossi, F Bordoni, A Fumagalli, L

Citation: P. Lissoni et al., Negative influence of morphine on the efficacy of interleukin-2 cancer immunotherapy, INT J IMM T, 15(1), 1999, pp. 31-34